Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049683 | 0.87 | CA12 (0.50) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL9699937 | 0.79 | CA12 (0.47) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL1463156 | 0.77 | CA9 (0.50) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL995389 | 0.77 | CA12 (0.50) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL230481 | 0.77 | CA9 (0.50) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL3259642 | 0.77 | CA1 (0.50) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL9179277 | 0.77 | RET (0.53) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL6129786 | 0.77 | CA12 (0.46) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL6740547 | 0.76 | CA12 (0.48) | CA12CA9USP2KMT2ACA1 | |
| SCHEMBL9637088 | 0.76 | CA12 (0.53) | CA12CA9USP2KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380918-A1 | PRODRUGS OF TAPINAROF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | claimed |
| WO-2023014927-A1 | PRODRUGS OF TAPINAROF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-02-09 | — | — | WO | claimed |
| US-20220007639-A1 | Arthropod Pest Control Compositions, Kits and Uses Thereof | INSCENT, INC. (US) | 2022-01-13 | — | — | US | claimed |
| US-11129380-B2 | Arthropod pest control compositions, kits and uses thereof | INSCENT, INC. (US) | 2021-09-28 | — | — | US | claimed |
| US-10744355-B2 | Heat resistant systems and methods | GOODRICH CORPORATION (US) | 2020-08-18 | — | — | US | claimed |
| EP-3648597-A1 | ARTHROPOD PEST CONTROL COMPOSITIONS, KITS AND USES THEREOF | Inscent, Inc. (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3630192-A1 | WATER-SOLUBLE POLYSACCHARIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USES | Jointherapeutics S.r.l. (IT) | 2020-04-08 | — | — | EP | claimed |
| CN-109338420-A | A kind of neutral electrotinning electrolyte of environmental protection | 江苏艾森半导体材料股份有限公司 | 2019-02-15 | — | — | CN | claimed |
| US-20190038653-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES | TETARD, INC. | 2019-02-07 | — | — | US | claimed |
| WO-2018220537-A1 | ADJUVANT SUPPLEMENT FOR ONCOLOGICAL PATIENTS | RAVERA, Ugo (IT) | 2018-12-06 | — | — | WO | claimed |
| WO-2001082971-A2 | CYCLODEXTRIN CONTAINING GLYCOPEPTIDE ANTIBIOTIC COMPOSITIONS | THERAVANCE, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| US-6183994-B1 | SIMPLE METHOD BY REACTING MONO-, DI- OR OLIGOSACCHARIDE, GLYCOSIDE, OR DERIVATIVE WITH AMINODEOXY MONO-, DI-, OR OLIGOSACCHARIDE, OR GLYCOSIDE IN PRESENCE OF RECOMBINANT GLYCOSIDASE, THEN OPTIONALLY ISOLATING AMINO-DEOXY SACCHARIDE | BIOFLEXIN AB (SE) | 2001-02-06 | — | — | US | claimed |
| EP-0863761-A1 | TOPICAL COMPOSITIONS CONTAINING A BETA-CYCLODEXTRIN AND AN AMINO POLYSACCHARIDE | Everest-Todd Research & Development Ltd. (GB) | 1998-09-16 | — | — | EP | claimed |
| WO-1997017977-A1 | TOPICAL COMPOSITIONS CONTAINING A BETA-CYCLODEXTRIN AND AN AMINO POLYSACCHARIDE | EVEREST-TODD RESEARCH & DEVELOPMENT LIMITED (GB) | 1997-05-22 | — | — | WO | claimed |
| US-5563252-A | REACTING AQUEOUS SOLUTION OF A SACCHARIDE AND AN AMINE WITH HYDROGEN IN PRESENCE OF CATALYST TO PRODUCE AMINOSACCHARIDE, REACTING INTERMEDIATE WITH 3-ISOPROPENYL-ALPHA-ALPHA-DIMETHYLBENZYLISOCYANATE | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| EP-0533692-A4 | MITOMYCIN DERIVATIVES HAVING REDUCED BONE MARROW TOXICITY, PROCESSES FOR THEIR PREPARATION, AND THE USES THEREOF | UNIV GEORGETOWN (US) | 1995-03-22 | — | — | EP | claimed |
| EP-0533692-A1 | MITOMYCIN DERIVATIVES HAVING REDUCED BONE MARROW TOXICITY, PROCESSES FOR THEIR PREPARATION, AND THE USES THEREOF | GEORGETOWN UNIVERSITY (US) | 1993-03-31 | — | — | EP | claimed |
| US-5091523-A | Bactericides, antitumor agent | GEORGETOWN UNIVERSITY (US) | 1992-02-25 | — | — | US | claimed |
| WO-1991016049-A1 | MITOMYCIN DERIVATIVES HAVING REDUCED BONE MARROW TOXICITY, PROCESSES FOR THEIR PREPARATION, AND THE USES THEREOF | GEORGETOWN UNIVERSITY (US) | 1991-10-31 | — | — | WO | claimed |
| US-4447562-A | Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions | IVANI EDWARD J | 1984-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038653-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES | TNF, PTGES, PTGES2 | CA12 2010/4885CA9 1750/4885USP2 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.